Combination therapies impact NAFLD more than singular therapy

Combining therapies with different mechanisms of action to treat non-alcoholic fatty liver disease resulted in greater reduction in liver-related measures, according to a presenter at The Liver Meeting Digital Experience.“In this randomized, 24-week, phase 2a trial, both semaglutide and combination regimens including semaglutide, firsocostat and/or cilofexor were well tolerated in NASH patients with mild-to-moderate fibrosis,” Naim Alkhouri, MD, from Arizona Liver Health, said. “Despite similar relative reductions in body weight vs. semaglutide, the combination regimens ledRead More

Share on facebook
Share on twitter
Share on linkedin